Exagen Inc

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exagen Inc reports robust Q1 revenue growth and strategic expansion

Exagen Inc's Q1 performance reflects strong revenue growth and improved financial outlook, driven by enhanced ASP and strategic initiatives.
Despite challenges in initial demand impact and regulatory monitoring, the company remains optimistic about future growth prospects and market positioning.
With a focus on innovation, market expansion, and operational efficiency, Exagen Inc aims to capitalize on opportunities for sustained growth and competitive advantage.

Exagen Inc reports strong Q2 performance, eyes growth through innovation

Exagen Inc's Q2 performance reflects significant improvement in financial metrics, revenue growth, and progress towards profitability, driven by increased clinical adoption and strategic initiatives.
The company's focus on innovation, market expansion, and customer engagement through new markers, biopharma contracts, and educational campaigns positions them for sustained growth and competitive advantage.
While challenges persist in achieving profitability and market acceptance, Exagen's proactive approach to addressing these hurdles and leveraging opportunities bodes well for their future success and market leadership.

Exagen Inc reports progress in revenue growth and innovation initiatives

Exagen Inc's Q3 2024 earnings call highlighted both achievements and challenges, with a focus on revenue growth, innovation, and operational improvements. The company is poised for growth with upcoming product launches and a strategic approach to enhancing the clinician experience. Challenges remain in achieving profitability and managing capacity expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB) with appointment of seven doctors and rheumatology experts. The SAB includes Stanley Cohen, MD; Andrew Concoff, MD, FACR, CAQSM; Kevin Deane, MD, PhD; Paul J. DeMarco, MD; Harris Perlman, PhD; Eric Ruderman, MD; and Marina Sirota, PhD.

Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board

SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum, which takes place March 22-23, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, March 23rd at 3:45 PM ET. Interested parties may access the live webcast of the fireside chat using a link on Exagen's website at investors.exagen.com/events.

Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31, 2021 after the market close on Tuesday, March 22, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM ET (1:30 PM PT).

Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 15-17, 2022. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, February 16 at 2:00 PM ET, which is accessible to conference attendees. Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through BTIG.

Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license agreement. The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients. Both parties will contribute to the development of the patent-pending assays, leading to the commercialization of novel molecular assays that segment patients according to gene expression in their synovial tissue biopsies.

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. From November 22nd to December 2nd, presentations will be available for registered attendees via the Piper Sandler conference site. Exagen will be participating in one-on-one meetings on December 1st. Meetings can be requested exclusively via Piper Sandler.

Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Exagen Inc. (XGN) CEO Ron Rocca on Q3 2021 Results - Earnings Call Transcript

Exagen (NASDAQ:XGN) reported its Q3 earnings results on Wednesday, November 10, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Exagen: Q3 Earnings Insights

Exagen Inc. (XGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Exagen Inc. (XGN) Q3 Earnings Expected to Decline

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered service with Inland Empire Health Plan (IEHP), providing enhanced care to over 1.4 million members. The agreement also makes AVISE diagnostic testing available as an in-network benefit.

Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus

SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innovatus Capital Partners, LLC (“Innovatus”). The amended agreement provides a $27.2 million, 5-year term loan at 8.0% interest, of which 2.0% is paid in-kind in the form of additional term loans. Additional information regarding the amendment is available in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2021.

Exagen Inc. Announces $27.2 Million Debt Refinancing

SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 27-30th, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Monday, September 27th at 2:40 PM EDT.

Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

Exagen Inc (NASDAQ: XGN) shares are moving after the Company's Q2 2021 revenue increased 43% Y/Y to $12.8 million due to increased testing volumes, beating the consensus of $11.48 million. Its flagship AVISE CTD test, including AVISE Lupus, raked in $10.4 million in sales with the 94% Y/Y growth, indicating an acceleration from ~22% YoY recorded in Q1 2021.

Exagen Stock Gains As Q2 Financials Surpass Street Expectations

The stock price of Exagen Inc. (Nasdaq: XGN) increased by over 34% during intraday trading. This is why it happened.

XGN Stock Price Increases Over 34% Intraday: Why It Happened

Exagen, Inc. (XGN) CEO Ron Rocca on Q2 2021 Results - Earnings Call Transcript

Shares of Exagen (NASDAQ:XGN) fell after the company reported Q2 results. Quarterly Results Earnings per share were down 40.74% over the past year to ($0.38), which beat the estimate of ($0.44).

Exagen: Q2 Earnings Insights

Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters

Exagen Inc. Reports Second Quarter 2021 Results

SAN DIEGO, July 30, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the addition of Ms. Ana Hooker as an additional independent member to its Board of Directors, effective July 29, 2021.

Exagen Appoints Ana Hooker to Board of Directors

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference, which takes place August 10-12, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Thursday, August 12 at 12:00 PM EST.

Exagen Inc. to Participate in the Canaccord Genuity 41st Annual Growth Conference

SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2021 after the market close on Monday, August 9, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company's results at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Exagen to Announce Second Quarter 2021 Financial Results on August 9, 2021

Earnings Preview: Exagen Inc. (XGN) Q2 Earnings Expected to Decline

SAN DIEGO, July 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the publication of their latest clinical utility study in Lupus & Science Medicine, found here: https://lupus.bmj.com/content/8/1/e000528.full. This multi-center study demonstrated that the AVISE Lupus test helped increase confidence in ruling-in and ruling-out systemic lupus erythematosus (SLE) in patients suspected of this disease and informed appropriate treatment decisions.

AVISE® Lupus Test Demonstrates Statistically Significant Clinical Utility in Achieving a Definitive SLE Diagnosis and Positively Impacts Treatment Decisions

SAN DIEGO, June 18, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, is proud to announce the company's stockholders approved the election of Mr. Frank Stokes as an additional independent member to its Board of Directors at the Annual Meeting held on June 17, 2021. Mr. Stokes will also serve as Chair of the Audit Committee.

Exagen Elects Frank Stokes to Board of Directors

SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 41st Annual Growth Stock Conference which takes place June 1-3, 2021. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, June 2 at 11:20 AM EDT.

Exagen Inc. to Participate in the William Blair 41st Annual Growth Stock Conference

Exagen Inc. (XGN) CEO Ron Rocca on Q1 2021 Results - Earnings Call Transcript

News for Exagen Inc Stock (XGN)